{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:50:51Z","timestamp":1787860251488,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002691"],"award-info":[{"award-number":["82002691"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020QC068"],"award-info":[{"award-number":["ZR2020QC068"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41417-026-01013-y","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:43:04Z","timestamp":1776163384000},"page":"277-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["WTAP stabilized by USP7 contributes to enzalutamide resistance in prostate cancer via mediating AKT m6A-modification"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8555-4069","authenticated-orcid":false,"given":"Ruxue","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8857-929X","authenticated-orcid":false,"given":"Qingwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-6192","authenticated-orcid":false,"given":"Shuhong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2508-5552","authenticated-orcid":false,"given":"Qingxia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"1013_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1013_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479\u201399.","journal-title":"Annu Rev Med"},{"key":"1013_CR3","doi-asserted-by":"crossref","unstructured":"Cai MP, Song XL, Li XA, Chen MK, Guo JD, Yang DH, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Update. 2023;68:100962.","DOI":"10.1016\/j.drup.2023.100962"},{"key":"1013_CR4","doi-asserted-by":"crossref","unstructured":"Han D, Labaf M, Zhao YW, Owiredu J, Zhang SQ, Patel K, et al. Androgen receptor splice variants drive castrationresistant prostate cancer metastasis by activating distinct transcriptional programs. J Clin Invest. 2024;134:e168649.","DOI":"10.1172\/JCI168649"},{"key":"1013_CR5","doi-asserted-by":"crossref","unstructured":"Ji Y, Zhang RY, Han XL, Zhou JM. Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC. Eur J Med Chem. 2023;247:115077.","DOI":"10.1016\/j.ejmech.2022.115077"},{"key":"1013_CR6","doi-asserted-by":"crossref","unstructured":"Schweizer MT, Yu EY. Persistent androgen receptor addiction in castration-resistant prostate cancer. J Hematol Oncol. 2015;8:128.","DOI":"10.1186\/s13045-015-0225-2"},{"key":"1013_CR7","doi-asserted-by":"crossref","unstructured":"He YD, Xu WD, Xiao YT, Huang HJ, Gu D, Ren SC. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7:198.","DOI":"10.1038\/s41392-022-01042-7"},{"key":"1013_CR8","doi-asserted-by":"crossref","unstructured":"Mao NH, Lee YS, Salsabeel N, Zhang ZD, Li D, Kaur H, et al. Uncoupling of Akt and mTOR signaling drives resistance to Akt inhibition in PTEN loss prostate cancers. Sci Adv. 2025;11:eadq3802.","DOI":"10.1126\/sciadv.adq3802"},{"key":"1013_CR9","doi-asserted-by":"crossref","unstructured":"Rescigno P, Porta N, Finneran L, Riisnaes R, Figueiredo I, Carreira S, et al. Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: results from the randomized phase II RE-AKT trial. Eur J Cancer. 22024;205:114103.","DOI":"10.1016\/j.ejca.2024.114103"},{"key":"1013_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrm.2016.132","volume":"18","author":"BXS Zhao","year":"2017","unstructured":"Zhao BXS, Roundtree IA, He C. Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Bio. 2017;18:31\u201342.","journal-title":"Nat Rev Mol Cell Bio"},{"key":"1013_CR11","doi-asserted-by":"crossref","unstructured":"Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6:74.","DOI":"10.1038\/s41392-020-00450-x"},{"key":"1013_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00432-020-03373-w","volume":"147","author":"D Naren","year":"2021","unstructured":"Naren D, Yan T, Gong Y, Huang J, Zhang D, Sang L, et al. High Wilms\u2019 tumor 1 associating protein expression predicts poor prognosis in acute myeloid leukemia and regulates m(6)A methylation of MYC mRNA. J Cancer Res Clin Oncol. 2021;147:33\u201347.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1013_CR13","doi-asserted-by":"crossref","unstructured":"Kuai Y, Gong X, Ding LY, Li F, Lei LZ, Gong YQ, et al. Wilms\u2019 tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90. Cell Commun Signal. 2018;16:50.","DOI":"10.1186\/s12964-018-0258-6"},{"key":"1013_CR14","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1136\/gutjnl-2014-308614","volume":"65","author":"JW Zhang","year":"2016","unstructured":"Zhang JW, Tsoi H, Li XX, Wang H, Gao J, Wang KN, et al. Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP-WT1-TBL1 axis. Gut. 2016;65:1482\u201393.","journal-title":"Gut"},{"key":"1013_CR15","doi-asserted-by":"crossref","unstructured":"He RZ, Jiang J, Hu XL, Lei M, Li J, Luo WH, et al. Stabilization of UCA1 by N6-methyladenosine RNA methylation modification promotes colorectal cancer progression. Cancer Cell Int. 2021;21:616.","DOI":"10.1186\/s12935-021-02288-x"},{"key":"1013_CR16","doi-asserted-by":"crossref","unstructured":"Tang JY, Wang F, Cheng G, Si SH, Sun X, Han J, et al. Wilms\u2019 tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability. J Exp Clin Canc Res. 2018;37:40.","DOI":"10.1186\/s13046-018-0706-6"},{"key":"1013_CR17","doi-asserted-by":"crossref","unstructured":"Ou BC, Liu Y, Yang XW, Xu XJ, Yan YW, Zhang JJ. C5aR1-positive neutrophils promote breast cancer glycolysis through WTAP-dependent m6A methylation of ENO1. Cell Death Dis. 2021;12:737.","DOI":"10.1038\/s41419-021-04028-5"},{"key":"1013_CR18","doi-asserted-by":"publisher","first-page":"10935","DOI":"10.1080\/21655979.2021.2000198","volume":"12","author":"T Huang","year":"2021","unstructured":"Huang T, Cao LL, Feng NN, Xu B, Dong YJ, Wang M. N6-methyladenosine (m6A)-mediated lncRNA DLGAP1-AS1enhances breast canceradriamycin resistance through miR-299-3p\/WTAP feedback loop. Bioengineered. 2021;12:10935\u201344.","journal-title":"Bioengineered"},{"key":"1013_CR19","doi-asserted-by":"crossref","unstructured":"Hu QX, Yin JL, Zhao SJ, Wang YB, Shi RX, Yan KQ, et al. ZFHX3 acts as a tumor suppressor in prostate cancer by targeting FTO-mediated m6A demethylation. Cell Death Discov. 2024;10:284.","DOI":"10.1038\/s41420-024-02060-w"},{"key":"1013_CR20","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1158\/0008-5472.CAN-20-1965","volume":"81","author":"L Gao","year":"2021","unstructured":"Gao L, Zhang W, Zhang J, Liu J, Sun F, Liu H, et al. KIF15-mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate cancer. Cancer Res. 2021;81:1026\u201339.","journal-title":"Cancer Res"},{"key":"1013_CR21","doi-asserted-by":"crossref","unstructured":"Hu Q, Zhang B, Chen R, Fu C, A J, Fu X, et al. ZFHX3 is indispensable for ER\u03b2 to inhibit cell proliferation via MYC downregulation in prostate cancer cells. Oncogenesis. 2019;8:28.","DOI":"10.1038\/s41389-019-0138-y"},{"key":"1013_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.gpb.2019.09.006","volume":"18","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Liu W, Zhang HM, Xie GY, Miao YR, Xia M, et al. hTFtarget: a comprehensive database for regulations of human transcription factors and their targets. Genom Proteom Bioinform. 2020;18:120\u20138.","journal-title":"Genom Proteom Bioinform"},{"key":"1013_CR23","first-page":"1016","volume":"36,","author":"LT Nie","year":"2022","unstructured":"Nie LT, Wang C, Liu XG, Teng HQ, Li ST, Huang M, et al. USP7 substrates identified by proteomics analysis reveal the specificity of USP7. Gene Dev. 2022;36,:1016\u201330.","journal-title":"Gene Dev"},{"key":"1013_CR24","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1111\/j.1742-4658.2007.05952.x","volume":"274","author":"A Fern\u00e1ndez-Montalvan","year":"2007","unstructured":"Fern\u00e1ndez-Montalvan A, Bouwmeester T, Joberty G, Mader R, Mahnke M, Pierrat B, et al. Biochemical characterization of USP7 reveals post-translational modification sites and structural requirements for substrate processing and subcellular localization. FEBS J. 2007;274:4256\u201370.","journal-title":"FEBS J"},{"key":"1013_CR25","first-page":"900","volume":"27","author":"JW Qiu","year":"2025","unstructured":"Qiu JW, Zhao RR, Ma CZ, Wang QT, Li BY, Qi YH, et al. O-GlcNAcylation stabilized WTAP promotes GBM malignant progression in an N6-methyladenosine-dependent manner. Dev Oncol. 2025;27:900\u201315.","journal-title":"Dev Oncol"},{"key":"1013_CR26","doi-asserted-by":"crossref","unstructured":"Huang B, Cao D, Yuan X, Xiong YX, Chen BZ, Wang YJ, et al. USP7 deubiquitinates KRAS and promotes non-small cell lung cancer. Cell Rep. 2024;43:114917.","DOI":"10.1016\/j.celrep.2024.114917"},{"key":"1013_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41585-021-00438-4","volume":"18","author":"KT Schmidt","year":"2021","unstructured":"Schmidt KT, Huitema ADR, Chau CH, Figg WD. Resistance to second-generation androgen receptor antagonists in prostate cancer. Nat Rev Urol. 2021;18:209\u201326.","journal-title":"Nat Rev Urol"},{"key":"1013_CR28","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.annonc.2020.01.074","volume":"31","author":"MP Kolinsky","year":"2020","unstructured":"Kolinsky MP, Rescigno P, Bianchini D, Zafeirio Z, Mehra N, Mateo J, et al. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2020;31:619\u201325.","journal-title":"Ann Oncol"},{"key":"1013_CR29","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.gendis.2021.02.004","volume":"9","author":"ZY Feng","year":"2022","unstructured":"Feng ZY, Zhou FH, Tan MM, Wang TT, Chen Y, Xu WW, et al. Targeting m6A modification inhibits herpes virus 1 infection. Genes Dis. 2022;9:1114\u201328.","journal-title":"Genes Dis"},{"key":"1013_CR30","doi-asserted-by":"crossref","unstructured":"Zhou Y, Zeng P, Li YH, Zhang ZD, Cui QH. SRAMP: prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features. Nucleic Acids Res. 2016;44:e91.","DOI":"10.1093\/nar\/gkw104"},{"key":"1013_CR31","doi-asserted-by":"crossref","unstructured":"Li YQ, Liu D, Wang LL, Shao YL, Zhou HS, Hu YL, et al. WTAP-mediated m6A methylation of PHF19 facilitates cell cycle progression by remodeling the accessible chromatin landscape in t(8;21) AML. Oncogene. 2025;44:1504\u201316.","DOI":"10.1038\/s41388-025-03329-9"},{"key":"1013_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12943-019-1053-8","volume":"18","author":"Y Chen","year":"2019","unstructured":"Chen Y, Peng C, Chen J, Chen D, Yang B, He B, et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol Cancer. 2019;18:127.","journal-title":"Mol Cancer"},{"key":"1013_CR33","doi-asserted-by":"crossref","unstructured":"Liyanage C, Fernando A, Chamberlain A, Moradi A, Batra J. RNA m6a methylation regulator expression in castration-resistant prostate cancer progression and its genetic associations. Cancers. 2024;16:1303.","DOI":"10.3390\/cancers16071303"},{"key":"1013_CR34","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.molcel.2022.03.035","volume":"82","author":"EV Wasmuth","year":"2022","unstructured":"Wasmuth EV, Vanden Broeck A, LaClair JR, Hoover EA, Lawrence KE, Paknejad N, et al. Allosteric interactions prime androgen receptor dimerization and activation. Mol Cell. 2022;82:2021.","journal-title":"Mol Cell"},{"key":"1013_CR35","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/JCO.2002.10.018","volume":"20","author":"EP Gelmann","year":"2002","unstructured":"Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20:3001\u201315.","journal-title":"J Clin Oncol"},{"key":"1013_CR36","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/pros.23951","volume":"80","author":"HeWJ Shao","year":"2020","unstructured":"Shao HeWJ, Yu YY, Huang Y, Feng W, Li GL. JH. Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation. Prostate. 2020;80:367\u201375.","journal-title":"Prostate"},{"key":"1013_CR37","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1530\/ERC-12-0394","volume":"20","author":"RL Bitting","year":"2013","unstructured":"Bitting RL, Armstrong AJ. Targeting the PI3K\/Akt\/mTOR pathway in castration-resistant prostate cancer. Endocr-Relat Cancer. 2013;20:R83\u2013R99.","journal-title":"Endocr-Relat Cancer"},{"key":"1013_CR38","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.eururo.2014.08.006","volume":"67","author":"P Toren","year":"2015","unstructured":"Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, et al. Combination AZD5363 with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models. Eur Urol. 2015;67:986\u201390.","journal-title":"Eur Urol"},{"key":"1013_CR39","doi-asserted-by":"crossref","unstructured":"Xie WL, Liu NF, Wang XY, Wei L, Xie WY, Sheng XG. Wilms\u2019 tumor 1-associated protein contributes to chemo-resistance to cisplatin through the Wnt\/\u03b2-catenin pathway in endometrial cancer. Front Oncol. 2021;11:598344.","DOI":"10.3389\/fonc.2021.598344"},{"key":"1013_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2019.02.043","volume":"451","author":"BQ Li","year":"2019","unstructured":"Li BQ, Liang ZY, Seery S, Liu QF, You L, Zhang TP, et al. WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer. Cancer Lett. 2019;451:48\u201357.","journal-title":"Cancer Lett"},{"key":"1013_CR41","doi-asserted-by":"publisher","first-page":"17155","DOI":"10.18632\/aging.203062","volume":"13","author":"ZJ Zhu","year":"2021","unstructured":"Zhu ZJ, Pang Y, Jin G, Zhang HY, Wang WH, Liu JW, et al. Hypoxia induces chemoresistance of esophageal cancer cells to cisplatin through regulating the lncRNA-EMS\/miR-758-3p\/WTAP axis. Aging. 2021;13:17155\u201376.","journal-title":"Aging"},{"key":"1013_CR42","doi-asserted-by":"crossref","unstructured":"Liu J, Gu XY, Guan ZJ, Huang D, Xing HW, Zheng L Role of m6A modification in regulating the PI3K\/AKT signaling pathway in cancer. J Transl Med. 2023;21:774.","DOI":"10.1186\/s12967-023-04651-0"},{"key":"1013_CR43","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/s41556-018-0174-4","volume":"20","author":"J Liu","year":"2018","unstructured":"Liu J, Eckert MA, Harada BT, Liu SM, Lu ZK, Yu KK, et al. m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018;20:1074.","journal-title":"Nat Cell Biol"},{"key":"1013_CR44","doi-asserted-by":"crossref","unstructured":"Guan XQ, Wang YC, Yu WK, Wei Y, Lu Y, Dai EY, et al. Blocking ubiquitin-specific protease 7 induces ferroptosis in gastric cancer via targeting Stearoyl-CoA Desaturase. Adv Sci. 2024;11:e2307899.","DOI":"10.1002\/advs.202307899"},{"key":"1013_CR45","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41401-024-01263-2","volume":"45","author":"LL Sun","year":"2024","unstructured":"Sun LL, Zhao LN, Sun J, Yuan HF, Wang YF, Hou CY, et al. Inhibition of USP7 enhances CD8+ T cell activity in liver cancer by suppressing PRDM1-mediated FGL1 upregulation. Acta Pharmacol Sin. 2024;45:1686\u2013700.","journal-title":"Acta Pharmacol Sin"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01013-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01013-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01013-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:56:16Z","timestamp":1777013776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01013-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1013"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01013-y","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, and the study was vested with the authority to the Ethics Committee of Shandong Provincial Hospital of Shandong First Medical University (R202406110275). All the patients participating in the research have signed the informed consent form. The animal assays were officially permitted to the Animal Ethics Committee of Shandong Provincial Hospital of Shandong First Medical University (W202406110553).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}]}}